Plantar Fasciitis Treatment Market Report 2026

The plantar fasciitis treatment market size has grown exponentially in recent years. It will grow from $2.07 billion in 2025 to $2.55 billion in 2026 at a compound annual growth rate (CAGR) of 23.1%. The growth in the historic period can be attributed to increasing prevalence of foot and heel pain disorders, rising incidence of obesity-related foot conditions, growing participation in sports activities, improved availability of physical therapy services, expansion of orthopedic care facilities.

The plantar fasciitis treatment market size is expected to see exponential growth in the next few years. It will grow to $5.69 billion in 2030 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to increasing adoption of advanced diagnostic imaging, rising demand for personalized orthotic products, expansion of outpatient orthopedic treatments, growing focus on preventive musculoskeletal care, increasing integration of physical therapy in treatment protocols. Major trends in the forecast period include increasing adoption of non-invasive treatment options, rising use of shockwave and physical therapy modalities, growing demand for custom orthotic solutions, expansion of multidisciplinary foot care approaches, enhanced focus on early diagnosis and conservative care.

The increasing prevalence of diabetes is expected to drive the growth of the plantar fasciitis treatment market. Diabetes is a long-term medical condition marked by high blood glucose levels due to inadequate insulin production or the body’s inability to effectively use insulin. In individuals with diabetes, plantar fasciitis treatment is used to reduce foot pain and discomfort caused by inflammation of the plantar fascia, thereby improving mobility and lowering the risk of further complications. For instance, in 2023, according to a report published by the Health Data Institute, around 529 million people globally were living with diabetes. Estimates indicate that if current trends persist, this number could rise to 1.3 billion by 2050. Therefore, the growing prevalence of diabetes is driving the expansion of the plantar fasciitis treatment market.

Major companies operating in the plantar fasciitis treatment market are concentrating on technological innovations, such as wearable long-duration ultrasound devices for at-home soft tissue therapy, to enhance healing, reduce pain, and limit the need for invasive procedures. Wearable long-duration ultrasound devices deliver continuous, low-intensity ultrasonic energy directly to soft tissue, promoting blood circulation, oxygen delivery, and cellular repair, while offering a non-invasive alternative to conventional orthotics, pain medications, or corticosteroid injections. For instance, in June 2025, ZetrOZ Systems, a US-based medical device manufacturer, introduced the sam 2.0, an advanced wearable ultrasound device designed for plantar fasciitis treatment. The device provides multi-hour, low-intensity ultrasound therapy that supports collagen formation, accelerates soft tissue healing, reduces inflammation, and can be self-administered at home, offering patients a convenient, drug-free, and non-surgical treatment option.

In September 2024, Bansk Group, a US-based investment firm, acquired Foundation Wellness for an undisclosed amount. Through this acquisition, Bansk Group seeks to enhance its plantar fasciitis treatment portfolio by incorporating Foundation Wellness’s specialty orthotics, insoles, and foot care solutions, thereby broadening its range of offerings for foot pain relief. Foundation Wellness is a US-based company that supplies orthotics, footbeds or insoles, orthopedic braces, and wellness-focused foot care products specifically developed to address plantar fasciitis and other foot-related conditions.

Major companies operating in the plantar fasciitis treatment market are Bayer AG, Superfeet Worldwide LLC, Bauerfeind AG, Ottobock SE & Co. KGaA, Sanofi SA, Eli Lilly and Company, GlaxoSmithKline plc, Pfizer Inc., Bristol-Myers Squibb Company, Scholl’s Wellness Co., Hanger Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Smith & Nephew plc, Arthrex Inc., DJO Global Co., Medline Industries Inc., Bird & Cronin Inc., Aetrex Worldwide Inc., Zimmer Biomet Holdings Inc., Stryker Corporation, Breg Inc., TheraBand LLC, Foot Levelers Inc.

North America was the largest region in the plantar fasciitis treatment market in 2025. The regions covered in the plantar fasciitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plantar fasciitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the plantar fasciitis treatment market by increasing costs of imported shockwave therapy devices, orthopedic equipment, diagnostic imaging systems, and orthotic manufacturing materials. Hospitals and clinics in North America and Europe are most affected due to reliance on imported medical devices, while Asia-Pacific faces higher costs for advanced treatment equipment. These tariffs are raising treatment costs and slowing technology adoption. However, they are also encouraging domestic production of orthopedic devices, local sourcing of orthotic materials, and innovation in cost-efficient conservative treatment solutions.

The plantar fasciitis treatment market research report is one of a series of new reports that provides plantar fasciitis treatment market statistics, including plantar fasciitis treatment industry global market size, regional shares, competitors with a plantar fasciitis treatment market share, detailed plantar fasciitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the plantar fasciitis treatment industry. This plantar fasciitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plantar fasciitis treatment involves medical care or preventive interventions provided to assess the occurrence and recurrence of a degenerative condition affecting the thick band of tissue located at the bottom of the foot. Physical therapy plays a key role in the management of plantar fasciitis.

The primary types of plantar fasciitis treatment include medication therapy, orthotics, shockwave therapy, surgery, and others. Medication therapy involves treating diseases or conditions through the use of prescription or non-prescription drugs, including over-the-counter and herbal medications. Diagnosis is carried out through medical history assessment, physical examination, X-rays, radiography, and other methods, and these treatments are utilized by hospitals, clinics, and other healthcare settings.

The plantar fasciitis treatment market includes revenues earned by entities by provide extracorporeal shock wave therapy (ESWT), intracorporeal pneumatic shock wave therapy (IPST), inflammation-related pain drugs, and non-operative treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.